TIKACAD 90 contains ticagrelor which belongs to theroup of medicines called antiplatelet agents. It is used to reduce the rate of cardiovascular death, myocardial infarction and stroke in patients with acute coronary syndrome (ACS) or a history of myocardial infarction. It also reduces the rate of stent thrombosis in patients who have been stented for treatment of ACS. Ticagrelor stops clumping of blood cells called platelets, which is responsible for clot formation in diseased blood vessels of heart and brain and thus reduces the chances of a blood clot formation. It can be taken with or without food.
The most common side effect of taking this medicine are bleeding and bruising. Avoid concomitant use of ticagrelor and other oral anticoagulants like heparin or warfarin, as it may increase the risk of side effects. Do not take this medicine if you are suffering from any bleeding disorders or liver problems. This medicine is not recommended for use in pregnant or breastfeeding women and in children aged below 18 years.
USES OF TIKACAD 90
Prevents cardiovascular death, myocardial infarction and stroke in patients with ACS or myocardial infarction
HOW TIKACAD 90 WORKS
Ticagrelor is a potent P2Y12 receptor antagonist. In diseased blood vessels, platelets can form thrombus (blood clot) by binding to the arterial surface. Activated platelets produces ADP3 which binds to P2Y12 receptor and propagates thrombus formation. Ticagrelor reversibly binds to P2Y12 receptor instead of ADP3 and prevents the signal transduction and platelet activation, that can lead to blood clot formation.
DIRECTIONS FOR USE
Take this medicine as directed by your physician. It can be taken with or without food. Your doctor will decide the correct dose for you depending upon your condition. Swallow the medicine with alass of water. If you have trouble in swallowing the medicine, you can crush it and mix with half alass of water. Stir and drink immediately. Continue to take this medicine, as long as your doctor tells you to do so, to obtain better results.
SIDE EFFECTS OF TIKACAD 90
Signs of stroke (such as headache, feeling dizzy, sudden numbness of arm, leg or face, especially if only on one side of the body, confusion, difficulty in speaking, lack of co-ordination)
Pink, red or brown urine
Vomiting blood clots
Red or black stools
Thrombotic Thrombocytopenic Purpura (such as fever and purplish spots on skin or in mouth, with or without yellowing of skin or eyes, unexplained extreme tiredness or confusion)
Shortness of breath
Bleeding and bruising
Headache, feeling dizzy
Diarrhea, indigestion or constipation
Feeling sick (nausea)
Skin rash or itching
Gout (severe pain and swelling in joints)
Low blood pressure
Bleeding in the nose, stomach lining orums
Bleeding after surgery or from cuts
HOW TO MANAGE SIDE EFFECTS
Feeling sick (nausea):
Try taking this medicine with, or just after meal. Stick to simple meals. Do not eat rich or spicy food.
Eat fibre rich foods like fresh fruit, vegetables and cereals. Drink plenty of water. Exercise more regularly.
Drink lots of fluids, such as water or juice, to avoid dehydration. Do not take any medicines without speaking to a doctor.
Apply hot or cold-water bag on your head. Take rest in a quiet and dark room. Drink tea or coffee.
WARNING & PRECAUTIONS
TIKACAD 90 is not recommended for use in pregnant women unless necessary. Discuss the risks and benefits with your doctor.
TIKACAD 90 is not recommended for use in breastfeeding women unless necessary. Discuss the risks and benefits with your doctor.
DRIVING AND USING MACHINES
Do not drive or operate any machines if your ability is affected by this medicine.
Avoid consumption of alcohol while taking this medicine.
Do not take TIKACAD 90 if you are suffering from severe liver disease. Consult your doctor for advice.
Do not take this medicine if you are allergic to Ticagrelor.
TIKACAD 90 should be taken with caution in patients with asthma or other lung problems or breathing difficulties. Consult your doctor for advice.
TIKACAD 90 should be taken with caution in patients with abnormal heart rate. Consult your doctor for advice.
Talk to your doctor before taking this medicine, if you:
Have a recent serious injury, recent surgery, recent bleeding from your stomach orut or any other bleeding disorders
Suffer from hyperuricemia (increased uric acid levels in blood)
Talk to your doctor, if you are taking,
Other oral anticoagulants (e.g. heparin, warfarin)
Medicines used to treat high cholesterol levels (e.g. simvastatin or lovastatin)
Medicines used to treat epilepsy (e.g. phenytoin, carbamazepine and phenobarbital)
Medicines used to treat depression (e.g. paroxetine, nefazodone, sertraline and citalopram)
Medicines used to treat heart problems like heart failure (e.g. digoxin), abnormal heart rate (e.g. quinidine and diltiazem) or high blood pressure (e.g. propranolol, verapamil, captopril)
Non-steroidal anti-inflammatory drugs (used to treat pain) e.g. ibuprofen and naproxen
Rifampicin (used to treat tuberculosis)
Cyclosporine (used to avoidraft rejection)
Morphine and other opioids (used to treat severe pain)
Ketoconazole (used to treat fungal infections)
Clarithromycin (used to treat bacterial infections)
Ritonavir and atazanavir (used to treat HIV infection)
Cisapride (used to treat heartburn)
Ergot alkaloids (used to treat migraine headaches)
Drug : Ticagrelor
Pharmacological Category :
Antiplatelet agent, P2Y12 receptor antagonist
Therapeutic Indication : Heart attack and stroke
Dosage Forms : Tablet
Store at room temperature and keep out of reach of children.
FAQs ABOUT TIKACAD 90
Can TIKACAD 90 be crushed?
Yes. If you feel difficulty in swallowing this medicine, you can crush it and mix with halflass of water and drink it.
Can TIKACAD 90 cause shortness of breath?
Yes. This medicine may sometime cause shortness of breath in some individuals. Contact your doctor for advice.
1. Keith A.A. Fox, Harvey D. White, Bernard J.ersh and Lionel H. Opie. Antithrombotic Agents: Platelet Inhibitors, Acute Anticoagulants, Fibrinolytics and Chronic Anticoagulants. Drugs for the heart. 8th Edition. 2013. Page – 351-352.
2.erald. Briggs, Roger K. Freeman. T. A referenceuide to fetal and neonatal risk: Drugs in Pregnancy and Lactation, Tenth Edition. 2015. Page – 3799-3800.
3. Jolanta M Siller-Matula, Bernd Jilma. Ticagrelor: from discovery to Phase III clinical trial. NIH National Library of Medicine, National center of Biotechnology information. November 2010. [Accessed 27th October 2020] https://pubmed.ncbi.nlm.nih.gov/21142630/
4. Dominick J. Angiolillo ,eorge D. Dangas. Ticagrelor With Aspirin or Alone in High-Risk Patients After Coronary Intervention – TWILIGHT. American college of cardiology. March 2020. [Accessed 27th October 2020] https://www.acc.org/latest-in-cardiology/clinical-trials/2019/09/24/23/30/twilight
5. AstraZeneca AB; Electronic Medicines Compendium (EMC) [Revised on September 2019] Accessed 27th October 2020] https://www.medicines.org.uk/emc/files/pil.5767.pdf
6. AstraZeneca AB; Electronic Medicines Compendium (EMC) [Revised on September 2019] Accessed 27th October 2020] https://www.medicines.org.uk/emc/files/pil.7606.pdf
USEFUL DIAGNOSTIC TESTS
TICAGRELOR 90 mg